Tofflon Science and Technology Group Co., Ltd. (300171.SZ) manufactures and supplies pharmaceutical equipment, systems and engineering solutions for the global pharmaceutical and biotechnology industries; core products include freeze dryers, lyophilization systems, fermenters, bioreactors, centrifuges, separation and purification systems such as chromatography, ultrafiltration and nanofiltration, filling and packaging equipment, stainless steel tanks and pipe systems, inactivation systems, small molecule chemical synthesis systems, polypeptide synthesis systems, traditional Chinese medicine extraction systems, disposable reaction and filling systems, perfusion culture platforms, mRNA production platforms, gene carrier culture systems, cell and gene therapy equipment, single-use technologies and laboratory furniture; the company also provides process support, integrated manufacturing systems, pharma engineering, quality control services and contract manufacturing. Founded in 1993 and headquartered in Shanghai, China, Tofflon operates globally across more than 50 countries and regions, serving over 3,000 pharmaceutical companies with applications in liquid and lyophilized injectables, chemical APIs, bioengineering, vaccine production and pharma packaging. In 2024, the company completed a private placement of approximately US$356 million led by Shanghai Healthcare Capital and SDIC fund to expand production capacity and enhance its strategic positioning along the biopharma industry chain; in January 2025, Tofflon announced plans to co-invest 200 million yuan alongside partners including Guotou Pioneer and Junshi Biosciences in a 10 billion yuan biopharmaceutical M&A fund focused on mergers, acquisitions and industry consolidation.